New research shows use of the drugs in pregnancy is on the rise, particularly in the United States, and although teratogenic risks appear low, limitations are notable.
Increased fracture risk seen in short-term studies may have been due to hypovolemia or osmotic diuresis, resulting in falls, rather than an effect on bone.
South Korea: A claims-based study involving two independent Korean cohorts revealed that SGLT2 inhibitors are associated with a lower or similar risk of fracture versus incretin-based antidiabetic.
1. In this population cohort study, patients with gout who used sodium-glucose cotransporter-2 inhibitors (SGLT2is) experienced fewer recurrent flares than those using dipeptidyl peptidase 4 inhibitors (DPP-4is). 2. Those who used SGLT2 inhibitors also presented to the emergency department (ED) less frequently for gout-related visits than those using DPP-4is. Evidence Rating Level: 1 (Excellent) Study